Acrivon Therapeutics, Inc. (ACRV) — SEC Filings
Acrivon Therapeutics, Inc. (ACRV) — 32 SEC filings. Latest: ARS (Apr 30, 2026). Includes 15 8-K, 6 SC 13G/A, 5 10-Q.
View Acrivon Therapeutics, Inc. on SEC EDGAR
Overview
Acrivon Therapeutics, Inc. (ACRV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 30, 2026: Acrivon Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The company, located at 480 Arsenal Way, Suite 100, Watertown MA 02472, operates in the Pharmaceutical Preparations sector. This filing provides a comprehensive ov
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 29 neutral, 3 mixed. The dominant filing sentiment for Acrivon Therapeutics, Inc. is neutral.
Filing Type Overview
Acrivon Therapeutics, Inc. (ACRV) has filed 1 ARS, 5 10-Q, 15 8-K, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ACRV's 23 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$18.234M |
| EPS | -$0.47 |
| Debt-to-Equity | 0.13 |
| Cash Position | $129.254M |
| Operating Margin | N/A |
| Total Assets | $145.299M |
| Total Debt | $16.696M |
Key Executives
- Eric Devroe
- Kristina Masson
- Peter Blume-Jensen
- Peter Blume-Jensen, M.D., Ph.D.
- Peter Kolchinsky
Industry Context
Acrivon operates in the highly competitive and innovative oncology therapeutics market. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Companies like Acrivon focus on developing targeted therapies, often leveraging biomarker technologies to improve patient selection and treatment efficacy.
Top Tags
corporate-governance (5) · disclosure (5) · sec-filing (3) · 10-Q (3) · financial-condition (3) · filing (3) · pharmaceuticals (2) · Biotechnology (2) · Oncology (2) · Clinical Trials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period of Report | 2025-12-31 | The fiscal year end covered by the ARS filing. |
| Filing Date | 2026-04-30 | The date Acrivon Therapeutics, Inc. submitted its ARS filing. |
| Net Loss (Q3 2025) | $18.234M | Decreased from $22.441M in Q3 2024 |
| Net Loss (YTD Sep 2025) | $58.920M | Increased from $57.725M in YTD Sep 2024 |
| Research and Development Expenses (Q3 2025) | $13.648M | Decreased from $18.864M in Q3 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $35.405M | Decreased from $39.818M at Dec 31, 2024 |
| Short-term Investments (Sep 30, 2025) | $93.849M | Decreased from $139.662M at Dec 31, 2024 |
| Confirmed Overall Response Rate for ACR-368 | 35% | Observed in OncoSignature-positive endometrial cancer patients in Phase 2 trial |
| Tumor Shrinkage for ACR-368 | 80% | Observed in OncoSignature-positive endometrial cancer patients in Phase 2 trial |
| Common Shares Outstanding | 31,555,126 | As of November 7, 2025 |
| Total Stockholders' Equity (Sep 30, 2025) | $128.603M | Decreased from $176.786M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $48.428M | Slightly increased from $48.309M in YTD Sep 2024 |
| Net Loss | $40.7M | for the six months ended June 30, 2025, an increase from $35.3M in 2024 |
| Accumulated Deficit | $237.7M | as of June 30, 2025, up from $197.0M at December 31, 2024 |
| Research and Development Expenses | $31.6M | for the six months ended June 30, 2025, a 19% increase from $26.5M in 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Acrivon Therapeutics, Inc. (ACRV)?
Acrivon Therapeutics, Inc. has 32 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ACRV filings?
Across 32 filings, the sentiment breakdown is: 29 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Acrivon Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Acrivon Therapeutics, Inc. (ACRV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Acrivon Therapeutics, Inc.?
Key financial highlights from Acrivon Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ACRV?
The investment thesis for ACRV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Acrivon Therapeutics, Inc.?
Key executives identified across Acrivon Therapeutics, Inc.'s filings include Eric Devroe, Kristina Masson, Peter Blume-Jensen, Peter Blume-Jensen, M.D., Ph.D., Peter Kolchinsky.
What are the main risk factors for Acrivon Therapeutics, Inc. stock?
Of ACRV's 23 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Acrivon Therapeutics, Inc.?
Forward guidance and predictions for Acrivon Therapeutics, Inc. are extracted from SEC filings as they are enriched.